Evidence map›Paper›PMID 20939771›Full record

ReviewMolecular membrane biology2010

Enzyme-triggered nanomedicine: drug release strategies in cancer therapy.

Thomas L Andresen, David H Thompson, Thomas Kaasgaard

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Molecular membrane biology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

44 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Harnessing nanotechnology for cancer treatment.Frontiers in bioengineering and biotechnology · 2024
    Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Intracellular KFrontiers in bioengineering and biotechnology · 2022
    Article
  13. Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Thomas L AndresenTechnical University of Denmark, DTU Nanotech, Department of Micro- and Nanotechnology, Roskilde, Denmark. thomas.andresen@nanotech.dtu.dk
David H Thompson
Thomas Kaasgaard

Funding

Development of Bioresponsive Lipids for Intracellular DeliveryR01GM087016 · NIGMS · PURDUE UNIVERSITY · PI THOMPSON, DAVID H · 2009 to 2012
$1.2M
NIGMS NIH HHS GM087016NIGMS NIH HHS R01 GM087016
6 · The paper itself

Abstract

Nanomedicine as a field has emerged from the early success of nanoparticle-based drug delivery systems, in particular for treatment of cancer, and the advances made in nano- and biotechnology over the past decade. A prerequisite for nanoparticle-based drug delivery systems to be effective is that the drug payload is released at the target site. A large number of drug release strategies have been proposed that can be classified into certain areas. The simplest and most successful strategy so far, probably due to relative simplicity, is based on utilizing certain physico-chemical characteristics of drugs to obtain a slow drug leakage from the formulations after accumulation in the cancerous site. However, this strategy is only applicable to a relatively small range of drugs and cannot be applied to biologicals. Many advanced drug release strategies have therefore been investigated. Such strategies include utilization of heat, light and ultrasound sensitive systems and in particular pH sensitive systems where the lower pH in endosomes induces drug release. Highly interesting are enzyme sensitive systems where over-expressed disease-associated enzymes are utilized to trigger drug release. The enzyme-based strategies are particularly interesting as they require no prior knowledge of the tumour localization. The basis of this review is an evaluation of the current status of drug delivery strategies focused on triggered drug release by disease-associated enzymes. We limit ourselves to reviewing the liposome field, but the concepts and conclusions are equally important for polymer-based systems.

Indexed as

LiposomesAnimalsAntineoplastic AgentsDrug Delivery SystemsEnzymesEnzyme TherapyHumansMiceNanomedicineNanoparticlesNeoplasmsAntineoplastic AgentsEnzymesLiposomes

Identifiers

PMID20939771
PMCPMC6889806

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.